<DOC>
	<DOCNO>NCT02921620</DOCNO>
	<brief_summary>The study randomize , double blind , placebo-controlled study safety efficacy PRX-102 ERT naïve male patient randomize 1:1 . Patient age 14 45 year . Patients must diarrhea define ≥ 3 stool day average consistency ≥ 5.5 Bristol Stool Form Scale ( BSFS ) patient electronic diary moderate severe gastrointestinal symptom define Irritable Bowel Symptom Severity Score ( IBSSS ) Part 1 average &gt; 175 derive least two IBSSS assessment screen period . Patients receive intravenous infusion PRX-102 1 mg/kg placebo every two week 6 month .</brief_summary>
	<brief_title>Study Evaluate Safety EffIcacy PRX-102 Gastrointestinal Symptoms Naïve Fabry Disease</brief_title>
	<detailed_description />
	<mesh_term>Fabry Disease</mesh_term>
	<criteria>Males , age 1445 year , naïve enzyme replacement therapy ( ERT ) ERT chaperone treatment least 6 month negative antiPRX102 antibody A document diagnosis Fabry disease : Plasma and/or leucocyte alpha galactosidase activity ( activity assay ) less low limit normal ( LLN ) eGFR CKDEPI &gt; 30 ml/min/1.73 m2 Moderate severe gastrointestinal symptom define : Average score &gt; 175 least two Irritable Bowel Symptom Severity Score ( IBSSS ) Part 1 assessment randomization . Average stool consistency ≥ 5.5 Bristol Stool Form Scale ( BSFS ) patient diary 2 week prior randomization 4 week screen period ≥ 3 stool day consistency ≥ 5 BSFS week randomization . Completed electronic BSFS diary least 6 7 day week prior randomization AND least 11 14 day 2 week prior randomization . Patients evaluate rule gastrointestinal comorbidity Fabry disease responsible gastrointestinal symptom : . Medical History non Fabry gastrointestinal comorbidity ii . Occult blood stool iii . Stool culture bacteria parasites iv . Calprotectin stool v. Sigmoidoscopy Use kind laxative Initiation antidiarrheal medication screen period History renal dialysis transplantation Use , change dose , angiotensin convert enzyme ( ACE ) inhibitor angiotensin receptor blocker ( ARB ) less 4 week prior screen Cardiovascular event ( myocardial infarction , unstable angina ) 6 month period randomization Congestive heart failure NYHA Class IV Cerebrovascular event ( stroke , transient ischemic attack ) 6 month period randomization Known history hypersensitivity Gadolinium contrast agent Known allergy ERT Presence medical , emotional , behavioral psychological condition , judgment Investigator and/or Medical Director , would interfere patient 's compliance requirement study</criteria>
	<gender>Male</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Gastrointestinal symptom</keyword>
	<keyword>Diarrhea</keyword>
	<keyword>Abdominal pain</keyword>
</DOC>